Affordable Access

Access to the full text

Synergistic Effect of Pyrrolidine Dithiocarbamate and Cisplatin in Human Cervical Carcinoma

Authors
  • Zheng, Xiaodong1, 2
  • Lv, Jieqiang1
  • Shen, Qi1
  • Chen, Yumei2
  • Zhou, Qingfeng1
  • Zhang, Wenwen1
  • Zhu, Xueqiong1
  • 1 The Second Affiliated Hospital of Wenzhou Medical University, No. 109 Xueyuan Xi Road, Wenzhou, Zhejiang, 325027, China , Wenzhou, Zhejiang (China)
  • 2 The People’s Hospital of Wenzhou, Wenzhou, 325000, China , Wenzhou (China)
Type
Published Article
Journal
Reproductive Sciences
Publisher
SAGE Publications
Publication Date
Oct 01, 2014
Volume
21
Issue
10
Pages
1319–1325
Identifiers
DOI: 10.1177/1933719114525272
Source
Springer Nature
Keywords
License
Yellow

Abstract

We aimed to delineate how pyrrolidine dithiocarbamate (PDTC) affects nuclear factor κB (NF-κB) and to determine its antitumor activity alone and in combination with cisplatin in human cervical cancer SiHa cells. The SiHa cells were treated with various concentrations of PDTC and/or cisplatin at various time intervals. Cell proliferation and apoptosis were determined using a water-soluble tetrazolium salt 8 assay and flow cytometry. Electrophoretic mobility shift assay was used to assess NF-κB activity. Pyrrolidine dithiocarbamate (2.5-100 µmol/L) was found to inhibit the growth of SiHa cell lines. Cisplatin (0.01-20.0 μg/mL) and PDTC (2.5-20.0 µmol/L) combined demonstrated additive inhibitive effects on cell growth and increased the level of apoptosis. In addition, PDTC blocked cisplatin-induced activation of NF-κB, leading to enhanced apoptosis and increased chemosensitivity to cisplatin. Taken together, PDTC has significant potential as a chemotherapy agent, alone or in combination with cisplatin.

Report this publication

Statistics

Seen <100 times